Effect of erythropoietin combined with hypothermia on serum tau protein levels and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy

Although hypothermia therapy is effective to treat neonatal hypoxic-ischemic encephalopathy,many neonatal patients die or suffer from severe neurological dysfunction.Erythropoietin is considered one of the most promising neuroprotective agents.We hypothesized that erythropoietin combined with hypoth...

Full description

Saved in:
Bibliographic Details
Published inNeural regeneration research Vol. 12; no. 10; pp. 1655 - 1663
Main Authors Lv, Hong-Yan, Wu, Su-Jing, Wang, Qiu-Li, Yang, Li-Hong, Ren, Peng-Shun, Qiao, Bao-Jun, Wang, Zhi-Ying, Li, Jia-Hong, Gu, Xiu-Ling, Li, Lian-Xiang
Format Journal Article
LanguageEnglish
Published India Medknow Publications and Media Pvt. Ltd 01.10.2017
Medknow Publications & Media Pvt. Ltd
Department of Neural Development and Neural Pathology, Hebei University of Engineering School of Medicine, Handan, Hebei Province, China
Department of Neonatology, Handan Maternal and Child Health Care Hospital, Handan, Hebei Province, China
Department of Neonatal Pathology, Handan Maternal and Child Health Care Hospital, Handan, Hebei Province, China%Department of Neonatology, Handan Maternal and Child Health Care Hospital, Handan, Hebei Province, China%Department of Children's Rehabilitation, Handan Maternal and Child Health Care Hospital, Handan, Hebei Province, China%Department of Neonatal Pathology, Handan Maternal and Child Health Care Hospital, Handan, Hebei Province, China
Medknow Publications & Media Pvt Ltd
Wolters Kluwer Medknow Publications
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Although hypothermia therapy is effective to treat neonatal hypoxic-ischemic encephalopathy,many neonatal patients die or suffer from severe neurological dysfunction.Erythropoietin is considered one of the most promising neuroprotective agents.We hypothesized that erythropoietin combined with hypothermia will improve efficacy of neonatal hypoxic-ischemic encephalopathy treatment.In this study,41 neonates with moderate/severe hypoxic-ischemic encephalopathy were randomly divided into a control group(hypothermia alone for 72 hours,n = 20) and erythropoietin group(hypothermia + erythropoietin 200 IU/kg for 10 days,n = 21).Our results show that compared with the control group,serum tau protein levels were lower and neonatal behavioral neurological assessment scores higher in the erythropoietin group at 8 and 12 days.However,neurodevelopmental outcome was similar between the two groups at 9 months of age.These findings suggest that erythropoietin combined with hypothermia reduces serum tau protein levels and improves neonatal behavioral neurology outcome but does not affect long-term neurodevelopmental outcome.
Bibliography:nerve regeneration erythropoietin hypothermia hypoxic-ischemic encephalopathy neonate tau protein biomarkers prognosis neuroprotection neural regeneration
Although hypothermia therapy is effective to treat neonatal hypoxic-ischemic encephalopathy,many neonatal patients die or suffer from severe neurological dysfunction.Erythropoietin is considered one of the most promising neuroprotective agents.We hypothesized that erythropoietin combined with hypothermia will improve efficacy of neonatal hypoxic-ischemic encephalopathy treatment.In this study,41 neonates with moderate/severe hypoxic-ischemic encephalopathy were randomly divided into a control group(hypothermia alone for 72 hours,n = 20) and erythropoietin group(hypothermia + erythropoietin 200 IU/kg for 10 days,n = 21).Our results show that compared with the control group,serum tau protein levels were lower and neonatal behavioral neurological assessment scores higher in the erythropoietin group at 8 and 12 days.However,neurodevelopmental outcome was similar between the two groups at 9 months of age.These findings suggest that erythropoietin combined with hypothermia reduces serum tau protein levels and improves neonatal behavioral neurology outcome but does not affect long-term neurodevelopmental outcome.
11-5422/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: HYL and LXL participated in study con-ception and design, contributed to data interpretation and edited the paper. HYL, SJW, LHY, BJQ and PSR supervised the implementation of the initiation, collected and analyzed data. QLW, XLG and ZYW contributed to the neurological ex-amination and data analyses. LXL and JHL contributed to blood test. All authors approved the final version of the paper.
ISSN:1673-5374
1876-7958
DOI:10.4103/1673-5374.217338